Improving IEX Technology and IEX-MS Applications for Domain Specific Charge Variant Analysis of mAb

Significance of the Topic

Monoclonal antibodies (mAbs) are among the most important biotherapeutics, and their charge variant profile is a critical quality attribute that influences efficacy, stability, and safety. Ion exchange chromatography (IEX) coupled to mass spectrometry (MS) provides high-resolution separation and real-time identification of charge variants, enabling detailed domain-specific analysis of intact molecules and fragments.

Goals and Study Overview

The primary aim of this work was to improve IEX technology and develop online IEX–MS applications for domain-specific charge variant analysis of mAbs. The study focused on:

• Optimizing pH and salt gradient methods for robust IEX separations.
• Developing volatile buffer systems compatible with MS detection.
• Evaluating novel stationary phases and column hardware for extended lifetime and reproducibility.
• Demonstrating the workflow on intact mAbs and IdeS-digested subunits, including case studies with Infliximab biosimilar comparison and forced degradation of Trastuzumab.

Methodology and Instrumentation

This approach combined optimized chromatography and MS with focus on reproducibility and ease of use. Key elements included:

• IEX separations using pH gradients prepared from volatile IonHance™ CX-MS buffers (ammonium acetate, bicarbonate, formate).
• BioResolve SCX mAb columns with non-porous 3 µm polymeric particles carrying hydrophilic coating and sulfonic acid ligands.
• VanGuard FIT integrated guard cartridges to protect columns from particulate and chemical fouling while preserving resolution.
• Coupling to Waters ACQUITY I-Class UPLC and ACQUITY RDa mass detector for automated setup and high-quality MS data.
• IdeS digestion to generate Fc/2 and (Fab)2 subunits for domain-specific variant mapping.

Main Findings and Discussion

The study produced several notable outcomes:

• IonHance CX-MS buffers delivered highly reproducible pH gradients with inter-batch and long-term stability (up to 46 days at 40 °C) and minimal carryover.
• BioResolve SCX mAb columns demonstrated high peak capacity, robust selectivity, and extended lifetime when used with VanGuard FIT cartridges, resisting corrosion and fouling.
• Online IEX–MS allowed reliable identification of C-terminal lysine variants, deamidation, and glycoforms on both intact mAbs and subunits.
• Case study on an Infliximab biosimilar showed quantitative agreement of charge profiles by UV and MS-confirmed species assignments across 0K, 1K, and 2K lysine variants.
• Forced degradation of Trastuzumab at pH 8 highlighted an increase in acidic variants localized to the (Fab)2 domain, confirmed by IdeS subunit MS analysis.

Benefits and Practical Applications

This optimized IEX–MS workflow offers:

• High-resolution, reproducible charge variant profiling for intact and subunit analyses.
• Real-time MS identification of variant species, reducing reliance on offline assays.
• Streamlined buffer preparation and system setup suited for routine QC and regulatory submissions.
• Extended column life and stable performance for high-throughput laboratories.

Future Trends and Opportunities

To further broaden the adoption of LC–MS in biopharma analysis, future developments may include:

• Smaller, fully automated systems with self-diagnosis and simplified user interfaces.
• Enhanced informatics platforms for compliance-ready data processing and AI-driven variant detection.
• Integration of orthogonal techniques (e.g., cIEF) within unified workflows for comprehensive charge profiling.
• New buffer chemistries and column materials to push resolution limits and robustness under diverse stress conditions.

Conclusion

By combining advanced volatile buffer systems, purpose-built column technology, integrated guard cartridges, and MS detection, this work establishes a robust, reproducible platform for domain-specific charge variant analysis of mAbs. The approach meets the growing demands for high-quality data in R&D, QC, and regulatory settings.

References

• J Chromatogr A. 2017;1498:147–154.
• mAbs. 2010;2(6):613–624.
• BioDrugs. 2016;30:321–338.
• mAbs. 2019;11(3):489–499.
• Anal Chem. 2013;85:16469–16476.
• Anal Chem. 2013;85:138–146.
• Waters Application Note 720006475EN. Designing a new particle technology for robust charge variant analysis of mAbs. January 2019.
• Rogstad et al. J Am Soc Mass Spectrom. 2017;28:786–794.